EGFR and TTF-1 Gene Amplification in Surgically Resected Lung Adenocarcinomas: Clinicopathologic Significance and Effect on Response to EGFR-Tyrosine Kinase Inhibitors in Recurred Cases

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Tony Mok, Yi‐Long Wu, Sumitra Thongprasert et al. · New England Journal of Medicine · 2009 · 8.2K citations · Full text

Medicine, Oncology, Pharmacology +13

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

Eunice L. Kwak, Yung‐Jue Bang, D. Ross Camidge et al. · New England Journal of Medicine · 2010 · 4.5K citations

Medicine, Oncology, Pharmacology +14

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

Lecia V. Sequist, Belinda A. Waltman, Dora Dias‐Santagata et al. · Science Translational Medicine · 2011 · 3.6K citations · Full text

Medicine, Genetics, Oncology +17

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

Masahiro Fukuoka, Yi‐Long Wu, Sumitra Thongprasert et al. · Journal of Clinical Oncology · 2011 · 1.6K citations

Medicine, Oncology, Pharmacotherapy +17

Epidermal Growth Factor Receptor in Non–Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis

Fred R. Hirsch, Marileila Varella‐Garcia, Paul A. Bunn et al. · Journal of Clinical Oncology · 2003 · 1.5K citations

Medicine, Genetics, Oncology +17